Anal CancerPhase 3NCT00003596
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
A Phase 3 study testing cisplatin, fluorouracil and mitomycin C in people with Anal Cancer, run by Radiation Therapy Oncology Group at 485 sites in 2 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Anal Cancer
- What is being tested?
- cisplatin, fluorouracil and mitomycin C
- Type of treatment
- Surgery or procedure
- How many people
- 682 participants
- Where
- 485 sitesin 2 countries
- Study dates
- Oct 1998to Dec 2016
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed primary squamous, basaloid, or cloacogenic carcinoma of the anal canal, other than carcinoma in situ
- T2-4, Any N, M0 (stage II or III)
- No local or regional recurrence after local excision or abdominal peritoneal resection
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 60-100%
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 4,000/mm^3
- Absolute neutrophil count at least 1,800/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
Hepatic:
- Bilirubin less than 1.4 mg/dL
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 80 mL/min
Cardiovascular:
- No uncompensated heart disease
- No uncontrolled high blood pressure
Other:
- No AIDS
- No active systemic infection
- No uncontrolled diabetes
- No other prior malignancy within the past 5 years except nonmelanoma skin cancer
- No mental condition that would preclude study participation
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Prior epoetin alfa allowed in lieu of blood transfusions
Chemotherapy:
- At least 5 years since prior chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- At least 5 years since prior radiotherapy
Surgery:
- No prior surgery of anal canal except for biopsy of study site
Trial locations and contacts
485 sites in 2 countries.
301 sites in 2 countries
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
Akron City Hospital at Summa Health System
Akron, Ohio, 44304
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Hematology-Oncology Associates, PC
Albuquerque, New Mexico, 87106
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87106
Lovelace Medical Center at Lovelace Sandia Health System
Albuquerque, New Mexico, 87108
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
Emory University Hospital - Atlanta
Altanta, Georgia, 30322
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Harrington Cancer Center
Amarillo, Texas, 79106
McFarland Clinic, P.C.
Ames, Iowa, 50010
Alaska Regional Hospital
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48100
St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
DeCesaris Cancer Institute at Anne Arundel Medical Center
Annapolis, Maryland, 21401
South Central Kansas Regional Medical Center
Arkansas City, Kansas, 67005
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Randolph Hospital
Asheboro, North Carolina, 27203
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287-8936
CancerCare of Maine at Eastern Maine Medial Center
Bangor, Maine, 04401
Good Shepherd Hospital
Barrington, Illinois, 60010
Battle Creek Health System
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
St. Joseph Hospital Community Cancer Center
Bellingham, Washington, 98225
MeritCare Clinic - Bemidji
Bemidji, Minnesota, 56601
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94705
Mountainview Medical
Berlin Corners, Vermont, 05602
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
Mecosta County General Hospital
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, 35294
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Health System
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P.C.
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58501
St. Joseph Medical Center
Bloomington, Illinois, 61701
Bloomington Hospital
Bloomington, Indiana, 47403
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Mountain States Tumor Institute - Boise
Boise, Idaho, 83712
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Boulder Community Hospital
Boulder, Colorado, 80301
Cancer Treatment Center at the Medical Center - Bowling Green
Bowling Green, Kentucky, 42101
Brainerd Medical Center
Brainerd, Minnesota, 56401
Olympic Hematology and Oncology
Bremerton, Washington, 98310
SUNY Downstate Medical Center
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215
St. Joseph Regional Cancer Center
Bryan, Texas, 77802
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Mills-Peninsula Health Services
Burlingame, California, 94010
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Cancer Institute of New Jersey at the Cooper University Hospital
Camden, New Jersey, 08103
Graham Hospital
Canton, Illinois, 61520
University Hospitals Ireland Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
St. Francis Medical Center
Cape Girardeau, Missouri, 63701
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Memorial Hospital
Carthage, Illinois, 62321
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28203
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, 60611
Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 54601
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, 44106
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Huron Hospital Cancer Care Center
Cleveland, Ohio, 44112
Euclid Hospital
Cleveland, Ohio, 44119
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Hematology and Oncology
Clifton Springs, New York, 14432
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Missouri Cancer Associates
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, 43210
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Mount Diablo Regional Cancer Center
Concord, California, 94520
Bethke Cancer Center at Emerson Hospital
Concord, Massachusetts, 01742
Mercy Hospital
Coon Rapids, Minnesota, 55433
Louis Busch Hager Cancer Center at Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Grady Memorial Hospital
Delaware, Ohio, 43015
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Josephine Ford Cancer Center at Henry Ford Health System
Detroit, Michigan, 48202
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Cancer Care Center at Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
Delaware County Regional Cancer Center at Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Wendt Regional Cancer Center at Finley Hospital
Dubuque, Iowa, 52001
Cancer Care Center at St. Luke's Hospital
Duluth, Minnesota, 55805
CCOP - Duluth
Duluth, Minnesota, 55805
Miller-Dwan Medical Center
Duluth, Minnesota, 55805
St. Mary's - Duluth Clinic Cancer Center
Duluth, Minnesota, 55805
Luther Mildelfort Hospital
Eau Claire, Wisconsin, 54702
Midelfort Clinic - Luther
Eau Claire, Wisconsin, 54702
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Fairview Southdale Hospital
Edina, Minnesota, 55435
St. Anthony's Memorial Hospital
Effingham, Illinois, 62401
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital Cancer Center at Union Hospital
Elkton MD, Maryland, 21921
Swedish Medical Center
Englewood, Colorado, 80110
Eureka Hospital
Eureka, Illinois, 61530
Evanston Northwestern Health Care - Evanston Hospital
Evanston, Illinois, 60201
Providence Cancer Institute at Providence Everett Medical Center - Pacific Campus
Everett, Washington, 98201
Hudner Oncology Center at Saint Anne's Hospital
Fall River, Massachusetts, 02721
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Medical Group
Fargo, North Dakota, 58122
Hurley Medical Center
Flint, Michigan, 48502
Genesys Hurley Cancer Institute
Flint, Michigan, 48532
Great Lakes Cancer Institute at McLaren Regional Medical Center
Flint, Michigan, 48532
Central Wisconsin Cancer Program at Agnesian Health Care
Fond du Lac, Wisconsin, 54935
Front Range Cancer Specialists
Fort Collins, Colorado, 80524
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
21st Century Oncology - Fort Myers
Fort Myers, Florida, 33901
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Fremont Area Medical Center
Fremont, Nebraska, 68025
California Cancer Center - Woodward Park Office
Fresno, California, 93720
Mercy and Unity Cancer Center at Mercy and Unity Hospitals
Fridley, Minnesota, 55432
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Legacy Mount Hood Medical Center
Glesham, Oregon, 97030
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Wayne Radiation Oncology
Goldsboro, North Carolina, 27534
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Mercy Medical Center
Grand Rapids, Michigan, 49503
Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, 49503
Metropolitan Hospital
Grand Rapids, Michigan, 49506
Spectrum Health Hospital - Blodgett Campus
Grand Rapids, Michigan, 49506
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital
Green Bay, Wisconsin, 54301-3526
St. Vincent Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center
Green Bay, Wisconsin, 54303
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27401
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Greenville Hospital System Cancer Center
Greenville, South Carolina, 29605
CCOP - Greenville
Greenville, South Carolina, 29615
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
Virginia Oncology Associates - Hampton
Hampton, Virginia, 23666
Catskill Regional Medical Center
Harris, New York, 12742
Mason District Hospital
Havana, Illinois, 62644
Saint Rose Hospital
Hayward, California, 94545
Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Holland Community Hospital
Holland, Michigan, 49423
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Hopedale Medical Complex
Hopedale, Illinois, 61747
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
Baptist Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224-9980
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazooaa, Michigan, 49001
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160
CCOP - Kansas City
Kansas City, Missouri, 64131
Cancer Center at the Good Samaritan Health Systems
Kearney, Nebraska, 68847
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Fairfield Medical Center
Lancaster, Ohio, 43130
St. Mary Regional Cancer Center
Langhorne, Pennsylvania, 19047
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Sunrise Hospital and Medical Center
Las Vegas, Nevada, 89109
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Beebe Medical Center
Lewes, Delaware, 19958
Central Maine Medical Center
Lewiston, Maine, 04240
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Central Baptist Hospital
Lexington, Kentucky, 40503
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Bryan LGH Medical Center West
Lincoln, Nebraska, 68502
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
St. Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Valley Memorial Hospital
Livermore, California, 94550
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, 92354
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Monmouth Medical Center
Long Branch, New Jersey, 07740
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80502
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410
McDonough District Hospital
Macomb, Illinois, 61455
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center at Regional Medical Center of Hopkins County
Madisonville, Kentucky, 42431
CCOP - North Shore University Hospital
Manhasset, New York, 11030
St. John's Hospital
Maplewood, Minnesota, 55109
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Upper Michigan Cancer Center at Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
St. Luke's Hospital
Maumee, Ohio, 43537
Hillcrest Cancer Center at Hillcrest Hospital
Mayfield Heights, Ohio, 44124
Baptist Centers for Cancer Care
Memphis, Tennessee, 38146
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
Baptist-South Miami Regional Cancer Program
Miami, Florida, 33176
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middlesex Hospital Cancer Center
Middletown, Connecticut, 06457
Middletown Regional Hospital
Middletown, Ohio, 45044
South Jersey Healthcare Regional Cancer Center
Millville, New Jersey, 08332
Vince Lombardi Cancer Clinic at St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Fairview University Medical Center - University Campus
Minneapolis, Minnesota, 55455
Trinity Cancer Care Center
Minot, North Dakota, 58701
Providence Holy Cross Cancer Center
Mission Hills, California, 91346-9600
Alegent Health Community Memorial Hospital
Missouri Valley, Iowa, 51555
Mobile Infirmary Medical Center
Mobile, Alabama, 36607
Memorial Medical Center Cancer Services
Modesto, California, 95355
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Cancer Center at the Mountainside Hospital
Montclair, New Jersey, 07042
Chippewa County - Montevideo Hospital
Montevideo, Minnesota, 56265
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown, West Virginia, 26506
Fox Chase Virtua Health Cancer Program - Marlton
Mount Holly, New Jersey, 08060
Cancer Care Center at Skagit Valley Hospital
Mount Vernon, Washington, 98273
Cancer Center at Ball Memorial Hospital
Muncie, Indiana, 47303
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Hackley Hospital
Muskegon, Michigan, 49443
Edward Hospital Cancer Center
Naperville, Illinois, 60566
Tulane Cancer Center
New Orleans, Louisiana, 70112
New York Weill Cornell Cancer Center at Cornell University
New York, New York, 10021
CCOP - Christiana Care Health Services
Newark, Delaware, 19718
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Newton - Wellesley Hospital
Newton, Massachusetts, 02162
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
Leavey Cancer Center at Northridge Hospital Medical Center
Northridge, California, 91325
Highland General Hospital
Oakland, California, 94602
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Summit Medical Center
Oakland, California, 94609
McKay-Dee Hospital Center
Ogden, Utah, 84403
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha
Omaha, Nebraska, 68114
About this study
Official title: A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus radiation therapy for anal cancer.
PURPOSE: This randomized phase III trial is studying fluorouracil and mitomycin plus radiation therapy to see how well it works compared to fluorouracil and cisplatin plus radiation therapy in treating patients with stage II or stage III anal cancer.
Read the detailed description
OBJECTIVES:
- Compare the initial and total local and distant failure rates in patients with anal canal cancer treated with either fluorouracil (5-FU) plus mitomycin concurrently with radiotherapy or 5-FU plus cisplatin followed by 5-FU plus cisplatin concurrently with radiotherapy.
- Identify any differences in local control and colostomy rates at 2 years in patients treated with these regimens.
- Determine any difference in colostomy free, disease free, or overall survival in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Evaluate the prognostic effects of tumor markers P53 overexpression, human papilloma virus status, and enzyme HAP1 in patients treated with these regimens.
OUTLINE: This is a randomized study. Patients are stratified according to gender, nodal status (positive vs negative), and primary tumor size (greater than 2 cm to 5 cm vs greater than 5 cm). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive fluorouracil (5-FU) IV continuously over 96 hours beginning on days 1 and 29 and mitomycin IV on days 1 and 29 with concurrent radiotherapy.
- Arm II: Patients receive induction chemotherapy comprising 5-FU IV continuously over 96 hours beginning on days 1, 29, 57, and 85 and cisplatin IV over 1 hour on days 1, 29, 57, and 85. Beginning on day 57, patients receive concurrent radiotherapy.
In both arms, radiotherapy is administered daily, 5 days a week, for 5-6.5 weeks. Patients with T3, T4, or N+ lesions or T2 lesions with residual disease receive additional radiotherapy to a reduced field.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 650 patients will be accrued for this study within 5 years.
- Conditions
- Anal Cancer
- Being tested
- cisplatin, fluorouracil, mitomycin C, radiation therapy
- Keywords
- stage II anal cancer, stage III anal cancer, squamous cell carcinoma of the anus, cloacogenic carcinoma of the anus, basaloid carcinoma of the anus
- Medical subject headings
- Anus Neoplasms, Anal Canal Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cisplatinDrug
fluorouracilDrug
mitomycin CDrug
radiation therapyRadiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startOct 1998
- Primary completionOct 2005
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Anal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Enrolment
- 682 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, Cancer and Leukemia Group B, SWOG Cancer Research Network, North Central Cancer Treatment Group
- Responsible party
- Sponsor
- Investigators
- Jaffer A. Ajani, MD, Study chair, M.D. Anderson Cancer CenterAl B. Benson, MD, FACP, Study chair, Robert H. Lurie Cancer CenterJoel E. Tepper, MD, Study chair, UNC Lineberger Comprehensive Cancer CenterJohn S. MacDonald, MD, Study chair, Beth Israel Comprehensive Cancer Center - West Side CampusMichael G. Haddock, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00003596
- Sponsor's protocol ID
- RTOG-9811
- Other IDs
- CDR0000066667, CALGB-89808, ECOG-R9811, NCCTG-R9811, SWOG-R9811, GUMC-00125
- Status last verified
- Dec 2016
- First submitted
- 1 Nov 1999
- Last updated
- 4 Jan 2017
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 1;28(34):5061-6. doi: 10.1200/JCO.2010.29.1351. Epub 2010 Oct 18.
PubMed 20956625Glynne-Jones R, Mawdsley S. Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? Nat Clin Pract Oncol. 2008 Dec;5(12):692-3. doi: 10.1038/ncponc1258. Epub 2008 Oct 14.
PubMed 18852720Gunderson LL, Winter KA, Ajani JA, et al.: Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. [Abstract] J Clin Oncol 29 (Suppl 15): A-4005, 2011.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 1;116(17):4007-13. doi: 10.1002/cncr.25188.
PubMed 20564111Gunderson LL, Moughan J, Ajani JA, et al.: Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in U.S. GI Intergroup RTOG 98-11 phase III trial. [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22-24 January 2010, Orlando, Florida. A-285, 2010.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 1;27(7):1116-21. doi: 10.1200/JCO.2008.19.6857. Epub 2009 Jan 12.
PubMed 19139424Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.
PubMed 18430910Ajani JA, Winter KA, Gunderson LL, et al.: Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. [Abstract] J Clin Oncol 24 (Suppl 18): A-4009, 2006.
Gunderson LL, Winter KA, Ajani JA, et al.: Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-43, S24, 2006.
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10;30(35):4344-51. doi: 10.1200/JCO.2012.43.8085. Epub 2012 Nov 13.
PubMed 23150707
Study at a glance
From the registry record, last updated by the sponsor on 4 Jan 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal
- ClinicalTrials.gov ID
- NCT00003596
- Acronym / sponsor ID
- RTOG-9811
- Conditions
- Anal Cancer
- Keywords
- stage II anal cancer, stage III anal cancer, squamous cell carcinoma of the anus, cloacogenic carcinoma of the anus, basaloid carcinoma of the anus
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 682 participants (actual)
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI), Eastern Cooperative Oncology Group, Cancer and Leukemia Group B, SWOG Cancer Research Network, North Central Cancer Treatment Group
- Study start
- Oct 1998
- Primary completion
- Oct 2005 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus radiation therapy for anal cancer.
PURPOSE: This randomized phase III trial is studying fluorouracil and mitomycin plus radiation therapy to see how well it works compared to fluorouracil and cisplatin plus radiation therapy in treating patients with stage II or stage III anal cancer.
Detailed description
OBJECTIVES:
- Compare the initial and total local and distant failure rates in patients with anal canal cancer treated with either fluorouracil (5-FU) plus mitomycin concurrently with radiotherapy or 5-FU plus cisplatin followed by 5-FU plus cisplatin concurrently with radiotherapy.
- Identify any differences in local control and colostomy rates at 2 years in patients treated with these regimens.
- Determine any difference in colostomy free, disease free, or overall survival in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Evaluate the prognostic effects of tumor markers P53 overexpression, human papilloma virus status, and enzyme HAP1 in patients treated with these regimens.
OUTLINE: This is a randomized study. Patients are stratified according to gender, nodal status (positive vs negative), and primary tumor size (greater than 2 cm to 5 cm vs greater than 5 cm). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive fluorouracil (5-FU) IV continuously over 96 hours beginning on days 1 and 29 and mitomycin IV on days 1 and 29 with concurrent radiotherapy.
- Arm II: Patients receive induction chemotherapy comprising 5-FU IV continuously over 96 hours beginning on days 1, 29, 57, and 85 and cisplatin IV over 1 hour on days 1, 29, 57, and 85. Beginning on day 57, patients receive concurrent radiotherapy.
In both arms, radiotherapy is administered daily, 5 days a week, for 5-6.5 weeks. Patients with T3, T4, or N+ lesions or T2 lesions with residual disease receive additional radiotherapy to a reduced field.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 650 patients will be accrued for this study within 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cisplatin | Drug | – |
| fluorouracil | Drug | – |
| mitomycin C | Drug | – |
| radiation therapy | Radiation | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jan 2017.
- Background: PubMed 20956625Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 1;28(34):5061-6. doi: 10.1200/JCO.2010.29.1351. Epub 2010 Oct 18.
- Background: PubMed 18852720Glynne-Jones R, Mawdsley S. Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? Nat Clin Pract Oncol. 2008 Dec;5(12):692-3. doi: 10.1038/ncponc1258. Epub 2008 Oct 14.
- Results publicationGunderson LL, Winter KA, Ajani JA, et al.: Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. [Abstract] J Clin Oncol 29 (Suppl 15): A-4005, 2011.
- Results publication: PubMed 20564111Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 1;116(17):4007-13. doi: 10.1002/cncr.25188.
- Results publicationGunderson LL, Moughan J, Ajani JA, et al.: Anal carcinoma: Impact of TN category of disease on survival, disease relapse, and colostomy failure in U.S. GI Intergroup RTOG 98-11 phase III trial. [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22-24 January 2010, Orlando, Florida. A-285, 2010.
- Results publication: PubMed 19139424Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 1;27(7):1116-21. doi: 10.1200/JCO.2008.19.6857. Epub 2009 Jan 12.
- Results publication: PubMed 18430910Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914.
- Results publicationAjani JA, Winter KA, Gunderson LL, et al.: Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. [Abstract] J Clin Oncol 24 (Suppl 18): A-4009, 2006.
- Results publicationGunderson LL, Winter KA, Ajani JA, et al.: Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-43, S24, 2006.
- Derived from this study: PubMed 23150707Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10;30(35):4344-51. doi: 10.1200/JCO.2012.43.8085. Epub 2012 Nov 13.
Related trials for Anal Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Anal Cancer
Active, not recruitingPhase 2
Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.
Squamous Cell Carcinoma of the Anus Stage III
Recruiting
Distance-Based Exercise to Preserve Function and Prevent Disability
Localized Malignant Solid Neoplasm, Anal Cancer
Active, not recruitingPhase 2
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jaffer A. Ajani, MD study chair
M.D. Anderson Cancer Center
Al B. Benson, MD, FACP study chair
Robert H. Lurie Cancer Center
Joel E. Tepper, MD study chair
UNC Lineberger Comprehensive Cancer Center
485 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing cisplatin, fluorouracil and mitomycin C in people with Anal Cancer, run by Radiation Therapy Oncology Group at 485 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 485 sites in United States, South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00003596, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2017.